We're changing our website design on 27 August 2017.

Basal cell carcinoma

The PBS subsidises vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

Treatment with vismodegib can be subsidised through the PBS under section 85 of the National Health Act 1953 for patients with metastatic or locally advanced basal cell carcinoma.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing vismodegib.

Applications

Initial treatment

All initial authority approval applications to prescribe vismodegib for the treatment of basal cell carcinoma must be made in writing:

All applications must include a completed:

The patient cannot receive more than 16 weeks of treatment under this restriction.

Continuing treatment

All initial authority approval applications to prescribe vismodegib for the treatment of basal cell carcinoma must be made in writing:

All applications must include a completed:

The patient cannot receive more than 16 weeks of treatment under this restriction.

Further information

For more information contact the PBS Complex Drugs Programs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 4 April 2017

This information was printed Tuesday 22 August 2017 from humanservices.gov.au/health-professionals/enablers/basal-cell-carcinoma It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.